September 9, 2021 – Nabriva Therapeutics plc has entered into an agreement with Vizient to offer XENLETA, which treats community-acquired bacterial pneumonia (CABP), as a contracted product to Vizient’s Pharmacy Network Program.
Nabriva CEO Ted Schroeder commented, “We are excited by Vizient’s decision to enter into an agreement to make XENLETA available to their Hospital Pharmacy Network, enabling access across Vizient member hospitals, which make up more than half of U.S. hospitals. Based on data from the Healthcare Cost and Utilization Project, it is estimated approximately 3 million adults are diagnosed with CABP in the hospital setting annually. Importantly, many of these patients may be at increased risk for adverse effects associated with respiratory fluoroquinolone or reside in areas with a high (>25%) prevalence of macrolide resistance. We are enthusiastic about the opportunity to provide clinicians a short-course, IV and oral monotherapy treatment option that addresses these unmet medical needs for their CABP patients.”
Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $110 billion in annual purchasing volume, to improve patient outcomes and lower costs.